Sol Langermann - 31 Jan 2025 Form 4 Insider Report for NextCure, Inc. (NXTC)

Role
Chief Scientific Officer
Signature
/s/ Steven P. Cobourn, as attorney-in-fact for Sol Langermann
Issuer symbol
NXTC
Transactions as of
31 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Feb 2025, 18:22:38 UTC
Previous filing
02 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NXTC Employee Stock Option (Right to Buy) Award $0 +117,375 $0.000000 117,375 31 Jan 2025 Common Stock 117,375 $0.8048 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026.